News

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS

The authors of this review and meta-analysis of phase III trials evaluated the use of daratumumab for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. While the individual trials did not demonstrate a statistically significant survival benefit, the meta-analysis did showed improvement in both progression-free and overall survival with daratumumab for both standard-risk and …

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS Read More »

EFFICACY OF MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER WITH A BRCA MUTATION

Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated efficacy in several tumor types, including advanced ovarian cancer, breast, prostate, and pancreatic cancers. Olaparib is approved in the United States, the European Union, and other countries as maintenance treatment for women with germline or somatic BRCA-mutated advanced OC who are in response to first-line platinum-based chemotherapy …

EFFICACY OF MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER WITH A BRCA MUTATION Read More »

IMPLICATIONS OF TP53 ALLELIC STATE FOR GENOME STABILITY, CLINICAL PRESENTATION AND OUTCOMES IN MYELODYSPLASTIC SYNDROMES

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer. In patients with myelodysplastic síndromes (MDS), TP53 mutations are associated with high-risk disease, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies and dismal outcomes. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations. However, the …

IMPLICATIONS OF TP53 ALLELIC STATE FOR GENOME STABILITY, CLINICAL PRESENTATION AND OUTCOMES IN MYELODYSPLASTIC SYNDROMES Read More »

ASSOCIATION OF SPAG5 AND TREATMENT RESPONSE IN PATIENTS WITH ER-POSITIVE BREAST CANCER

Sperm-associated antigen 5 (SPAG5) represents a novel oncogene in estrogen receptor (ER)–positive luminal-B breast cancer. The authors of this study evaluated the association of SPAG5 gene and protein expression and treatment response in 12,270 patients with ER-positive breast cancer. Overexpression was associated with higher odds of a pathologic complete response. Furthermore, among women with SPAG …

ASSOCIATION OF SPAG5 AND TREATMENT RESPONSE IN PATIENTS WITH ER-POSITIVE BREAST CANCER Read More »

GENOMIC PROFILING OF SMOLDERING MULTIPLE MYELOMA IDENTIFIES PATIENTS AT A HIGH RISK OF DISEASE PROGRESSION

Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. We observed that most of …

GENOMIC PROFILING OF SMOLDERING MULTIPLE MYELOMA IDENTIFIES PATIENTS AT A HIGH RISK OF DISEASE PROGRESSION Read More »

NOVARTIS PIQRAY® RECEIVES POSITIVE CHMP OPINION TO TREAT HR+/HER2- ADVANCED BREAST CANCER WITH A PIK3CA MUTATION

Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of Piqray® (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer with …

NOVARTIS PIQRAY® RECEIVES POSITIVE CHMP OPINION TO TREAT HR+/HER2- ADVANCED BREAST CANCER WITH A PIK3CA MUTATION Read More »

FDA APPROVES FIRST THERAPY FOR PATIENTS WITH LUNG AND THYROID CANCERS WITH A CERTAIN GENETIC MUTATION OR FUSION

The U.S. Food and Drug Administration (FDA), approved Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers – in patients whose tumors have an alteration (mutation or fusion) in a specific gene (RET or “rearranged during transfection”). Retevmo is the first …

FDA APPROVES FIRST THERAPY FOR PATIENTS WITH LUNG AND THYROID CANCERS WITH A CERTAIN GENETIC MUTATION OR FUSION Read More »

KRAS GENE AMPLIFICATION IN COLORECTAL CANCER AND IMPACT ON RESPONSE TO EGFR-TARGETED THERAPY

KRAS mutations are the most common oncogenic event in colorectal cancer (CRC) progression and their occurrence is associated with lack of response to anti epidermal growth factor receptor (EGFR) targeted therapies. Using preclinical models and patients’ samples we recently reported that the emergence of KRAS mutations but also KRAS amplification is associated with acquired resistance …

KRAS GENE AMPLIFICATION IN COLORECTAL CANCER AND IMPACT ON RESPONSE TO EGFR-TARGETED THERAPY Read More »

FDA APPROVES FIRST NEW DRUG UNDER INTERNATIONAL COLLABORATION, A TREATMENT OPTION FOR PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

As part of Project Orbis, the U.S. Food and Drug Administration approved Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can’t be removed with surgery, or has spread to other parts of the body, including the brain, and who have received …

FDA APPROVES FIRST NEW DRUG UNDER INTERNATIONAL COLLABORATION, A TREATMENT OPTION FOR PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER Read More »

VALIDATION AND REFINEMENT OF THE REVISED 2017 EUROPEAN LEUKEMIANET GENETIC RISK STRATIFICATION OF ACUTE MYELOID LEUKEMIA

The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification of acute myeloid leukemia have been widely adopted, but have not yet been validated in large cohorts of AML patients. We studied 1116 newly diagnosed AML patients (age range, 18-86 years) who had received induction chemotherapy. Among 771 patients not selected by genetics, the …

VALIDATION AND REFINEMENT OF THE REVISED 2017 EUROPEAN LEUKEMIANET GENETIC RISK STRATIFICATION OF ACUTE MYELOID LEUKEMIA Read More »